Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Saliva test sits at the center of this dementia and brain health question.
While there is significant promise in saliva-based testing for dementia risk, a widely available $25 test is not yet available as of early 2026. The saliva testing landscape for Alzheimer’s disease and cognitive decline is rapidly evolving, with research showing that biomarkers in saliva can detect early cognitive changes—but current commercial options cost considerably more. The First Choice Neurology Alzheimer’s Risk Test, currently available through saliva collection, costs $599, while 23andMe’s genetic risk assessment runs $179. These tests analyze saliva for genetic variants and biomarkers associated with Alzheimer’s disease, though they remain research-focused tools rather than definitive diagnostic instruments.
This article explores what saliva-based dementia testing actually offers today, why costs are where they are, what research is happening, and when truly affordable options might realistically arrive. The excitement around saliva testing stems from a genuine scientific development: researchers have identified biomarkers in saliva that correlate with early cognitive decline and Alzheimer’s pathology. Unlike traditional diagnostic approaches that require invasive lumbar punctures (spinal taps) or expensive PET imaging scans, saliva testing is non-invasive, painless, and suitable for elderly patients who might struggle with other testing methods. However, the journey from laboratory discovery to an affordable, clinically validated test available at local clinics takes years of validation and regulatory approval—which is why $599 and $179 tests exist today, but the $25 version you’ve heard about likely remains in development or exists only in research settings.
Table of Contents
- What Dementia Saliva Tests Actually Measure Today
- Why Current Tests Cost More Than $25
- The Research Pipeline—What’s Coming Next
- How to Evaluate Current Testing Options
- Important Limitations and What These Tests Don’t Do
- What You Can Do Today While Waiting for Better Tests
- The Future of Dementia Screening—What Changes Are Coming
- Conclusion
What Dementia Saliva Tests Actually Measure Today
Saliva-based tests for dementia risk currently focus on two main approaches: genetic testing and biomarker detection. The 23andMe Genetic Risk Report ($179) analyzes your saliva sample for specific genetic variants—particularly the APOE4 gene—that increase the risk of developing Alzheimer’s disease. If you carry one copy of the APOE4 gene, your risk is elevated; two copies increases risk substantially. This genetic information is valuable for understanding your baseline risk, but genetics alone don’t determine whether you’ll develop dementia—environment, lifestyle, education level, and cardiovascular health all play significant roles.
The First Choice Neurology test ($599) goes further by detecting actual biomarkers that may indicate early brain changes. Researchers at the University of Alberta have identified three specific biomarkers in saliva that can detect mild cognitive impairment and Alzheimer’s disease, potentially years before cognitive symptoms appear. However, here’s the important limitation: these tests currently carry regulatory designations of “For Research Use Only” (RUO) and are explicitly “not for use in diagnostic procedures.” This means they cannot yet be used to diagnose dementia or make definitive medical decisions. Instead, they serve as one data point among many—useful for risk stratification and identifying people who should pursue further evaluation, but not a diagnosis on their own.
Why Current Tests Cost More Than $25
The price difference between what’s available today and the hypothetical $25 test illustrates how medical testing costs break down. A $599 test from First Choice Neurology includes several elements: laboratory analysis of biomarkers (not simple genetic variants, but actual protein and RNA signatures in your saliva), healthcare provider review and interpretation, a detailed report explaining your results in clinical context, and the operational costs of running a regulatory-compliant testing facility. The company must employ trained technicians, maintain quality control standards, manage patient data securely, and hold proper licenses.
The 23andMe test at $179 is less expensive partly because it’s a volume business model—millions of people use the service for ancestry and health reports, spreading fixed costs across a large customer base. However, even at $179, you’re paying for saliva analysis, data security, bioinformatics algorithms to identify genetic variants, and interpretation by licensed health professionals. A $25 test, if it exists anywhere right now, would almost certainly be a research study (where participants aren’t paying, or are paying a nominal fee to participate in validation studies) rather than a commercial product with quality guarantees and clinical accountability.
The Research Pipeline—What’s Coming Next
Multiple universities and biotech companies are actively working to make saliva-based dementia testing more accessible and affordable. Large clinical studies are underway comparing saliva biomarkers against gold-standard testing methods like cerebrospinal fluid analysis (from lumbar puncture), blood biomarkers, and PET imaging. A 2025 study published in Alzheimer’s & Dementia shows that research labs have successfully identified correlations between saliva biomarkers and Alzheimer’s pathology—the scientific foundation is solid.
The barrier now is scaling validation, obtaining regulatory approvals (FDA clearance in the U.S.), and building the infrastructure for mass production. What does this mean for the timeline? A truly affordable, widely available test ($25 range) would need to reach regulatory approval, achieve validation in large diverse populations, and establish reimbursement pathways through insurance. The best estimate from industry experts is that we’re 2-4 years away from wider clinical availability of more affordable tests, but that’s an estimate, not a guarantee. Someday, a simple saliva test might be something your primary care doctor orders as routinely as a cholesterol panel—but that day isn’t here yet in 2026.
How to Evaluate Current Testing Options
If you’re concerned about dementia risk, you have realistic options available today, though they’re not the $25 version. For genetic risk assessment, 23andMe ($179) gives you APOE4 status and ancestry information; it’s accessible, relatively affordable, and provides actionable information—if you learn you carry APOE4, you can focus on lifestyle interventions (exercise, Mediterranean diet, cognitive engagement, sleep quality, blood pressure management) that research shows can delay cognitive decline even in people with genetic risk.
If you want a more comprehensive biomarker assessment, the First Choice Neurology test ($599) available through their website offers detection of early changes, though you’ll want to discuss results with a neurologist or cognitive specialist who can put the findings in context. The important tradeoff: the 23andMe option is cheaper but gives you genetics only; the First Choice test is pricier but may detect active Alzheimer’s pathology earlier. For most people, especially those with a family history of dementia, starting with 23andMe is reasonable, then discussing results with your doctor to determine if further evaluation is warranted.
Important Limitations and What These Tests Don’t Do
A critical warning: neither 23andMe nor the First Choice test can diagnose dementia. If you’re already experiencing memory loss, confusion, or cognitive difficulties, you need a clinical evaluation by a neurologist or geriatrician—not just a biomarker test. These tests are for risk assessment in people without current cognitive symptoms. Additionally, a positive result (carrying APOE4 or showing early biomarkers) does not mean you will definitely develop dementia; many people with these markers never progress to cognitive decline, particularly if they maintain healthy lifestyle factors. Another limitation: these tests are not yet covered by insurance because they’re not FDA-approved for diagnostic use.
You’ll pay out-of-pocket. This creates equity issues—people with resources can access early risk information, while others cannot. That’s another reason the development of cheaper tests matters. Finally, test results can raise anxiety. Some people benefit from knowing their genetic risk because it motivates lifestyle change; others find the information psychologically burdensome without any current clinical action to take. Consider your own psychology before ordering—discuss the implications with a doctor first.
What You Can Do Today While Waiting for Better Tests
While we wait for the affordable, validated saliva test of the future, evidence-based interventions for dementia prevention are available right now and don’t require any test. The “FINGER” study (Finnish Geriatric Intervention Study) showed that a combination of cognitive training, physical exercise, diet optimization, vascular risk management, and social engagement reduced cognitive decline by 25-30% even in people at genetic risk.
You don’t need to wait for a $25 test to start exercising, eating Mediterranean-style meals, learning a new language, maintaining blood pressure control, sleeping 7-8 hours nightly, or staying socially connected. If you’re specifically worried because a parent or sibling developed dementia, talk to your primary care doctor now about cognitive screening (simple tests like the Montreal Cognitive Assessment or Mini-Cog that take 10-15 minutes), baseline brain imaging if appropriate, and cardiovascular health optimization. These clinical steps are available today and provide actionable information without waiting for new technology.
The Future of Dementia Screening—What Changes Are Coming
The dementia testing field is at an inflection point. Blood tests for Alzheimer’s biomarkers (like phosphorylated tau and amyloid-beta) have already made significant progress and some are moving toward clinical adoption—they’re less convenient than saliva (requires a needle draw) but more established. Saliva testing has the advantage of being completely non-invasive and suitable for home or clinic collection, which is why so much research investment is flowing into it.
Within 2-4 years, expect to see more saliva-based tests reaching FDA clearance, insurance coverage expanding, and costs declining as competition increases and manufacturing scales. The trajectory suggests that sometime in the next few years, a more affordable, clinically validated saliva test for dementia risk will likely become available—whether exactly $25 remains to be seen, but the direction is toward accessibility. When that happens, these tests will most likely be used as screening tools in primary care rather than diagnostic instruments, identifying people who need further evaluation. The key change-makers will be regulatory approval and insurance reimbursement, not just scientific discovery—the science is largely there already.
Conclusion
The saliva test for dementia risk you’ve heard about—specifically a $25 test available by next year—does not currently exist as a commercial or clinical product in 2026. What does exist is promising research, tests in development or available through specialty companies at higher price points ($179-$599), and a clear scientific foundation showing that saliva biomarkers can detect early Alzheimer’s pathology. The gap between the promising research and an affordable, widely available test reflects the time needed for regulatory validation, insurance reimbursement pathways, and manufacturing scale-up.
In the meantime, if you’re concerned about dementia risk, your best starting points are discussing genetic risk with your doctor (23andMe provides baseline genetic data for $179), maintaining the lifestyle factors we know prevent cognitive decline, and pursuing clinical evaluation through your primary care physician if you notice any cognitive changes. The future of affordable, non-invasive dementia screening is coming—just not quite as imminently as headlines sometimes suggest. Stay informed, maintain healthy habits, and check back in a few years for the truly accessible tests that research is building toward.
You Might Also Like
- Reagan vs Trump The Political Cost of Dementia Speculation
- How Service Dogs Are Being Trained Specifically for Dementia Patients and What They Cost
- Why 4 Out of 5 Doctors Do Not Mention the New Dementia Blood Test During Annual Physicals
For more, see Alzheimer’s Association — clinical trials.
